Q1 FY27 results: PAT up 56% YoY at Rs 2,459 lakhs, EPS restated

Pat Growth 25pctEbitda Margin ExpansionResults RestatedResults View source PDF Explain this filing

SYNCOMF · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+8.9%Reaction day

₹14.55

prior close

₹15.50

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%+8.6% vs market

Pharmaceuticals peers, median of 165sector-0.6%+9.5% vs sector

On the reaction day the stock moved 8.6 pts more than Nifty Microcap 250 and 9.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.6

10m

+0.3

15m

-0.8

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+8.9+0.4+8.6-0.6+9.5

Next day

+5.0+0.5+4.5-0.3+5.3

+2.4+0.6+1.8-0.7+3.1

+4.7+0.7+4.0-1.4+6.2

+7.2+1.1+6.1-1.1+8.3

+4.9+0.5+4.4-2.0+6.8

+11.7+1.3+10.4-1.4+13.1

15d

+47.4+0.5+46.8-1.0+48.3

+27.6-0.8+28.4-0.4+28.0

+59.3-0.9+60.3-3.2+62.5

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Syncom Formulations reported Q1 FY27 standalone results. Revenue from operations rose to Rs 12,465.95 lakhs from Rs 11,654.69 lakhs YoY. PAT jumped 56% to Rs 2,458.92 lakhs versus Rs 1,572.93 lakhs. PBT grew 58% to Rs 3,190.88 lakhs, with EBITDA margin expanding sharply on lower other expenses. EPS restated to 0.26 on PAT basis. Consolidated PAT also up 58% to Rs 2,484.68 lakhs. Auditor issued an unqualified limited review report.

Likely market impact

Strong earnings beat with PAT up 56% YoY on margin expansion. EPS methodology restated for Ind AS compliance.